PureTech Health plc (PRTC)
NASDAQ: PRTC · IEX Real-Time Price · USD
27.90
0.00 (0.00%)
At close: May 17, 2024, 12:00 AM
29.05
+1.15 (4.12%)
Pre-market: May 20, 2024, 8:34 AM EDT
PureTech Health Revenue
In the year 2023, PureTech Health had annual revenue of $3.33M, a decrease of -78.68%.
Revenue (ttm)
$3.33M
Revenue Growth
-78.68%
P/S Ratio
232.91
Revenue / Employee
$37,000
Employees
90
Market Cap
775.57M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
Dec 31, 2018 | 20.75M | 18.21M | 718.46% |
Dec 31, 2017 | 2.54M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Phibro Animal Health | 999.56M |
OrthoPediatrics | 161.83M |
Wave Life Sciences | 112.91M |
REGENXBIO | 86.73M |
CureVac | 59.73M |
Mesoblast | 7.25M |
Dianthus Therapeutics | 2.26M |
PRTC News
- 13 hours ago - PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share - Business Wire
- 11 days ago - PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting - Business Wire
- 13 days ago - PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments - Business Wire
- 25 days ago - PureTech Announces Annual Results for Year Ended December 31, 2023 - Business Wire
- 4 weeks ago - PureTech Health: Notice of Results - Business Wire
- 4 weeks ago - PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis - Business Wire
- 5 weeks ago - PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers - Business Wire
- 5 weeks ago - PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions - Business Wire